Send to

Choose Destination
J Ren Nutr. 2012 Nov;22(6):525-32. doi: 10.1053/j.jrn.2012.04.005. Epub 2012 Jun 13.

The effect of n-3 polyunsaturated fatty acids on plasma lipids and lipoproteins in patients with chronic renal failure--a meta-analysis of randomized controlled trials.

Author information

Department of Medical Statistics, West China School of Public Health, Sichuan University, Chengdu, Sichuan, People's Republic of China.



To systemically review and analyze the effect of n-3 polyunsaturated fatty acid (PUFA) consumption on plasma lipids and lipoproteins in patients with end-stage renal disease.


Systemic review, with meta-analysis of randomized controlled clinical trials.


We performed a systemic review and meta-analysis of the lipid-modulating effects of n-3 PUFAs by combining evidences from 10 randomized controlled trials including 557 patients with end-stage renal disease.


Pooled analysis revealed that n-3 PUFA intake significantly reduced serum triglyceride levels by -0.78 mmol/L (95% confidence interval: -1.12 to -0.44 mmol/L, P < .0001). Consumption of n-3 PUFAs also reduced the plasma low-density lipoprotein cholesterol levels by -0.09 mmol/L and elevated plasma high-density lipoprotein cholesterol levels by -0.25 mmol/L, but these changes were not statistically significant. Plasma levels of total cholesterols were elevated in both n-3 PUFA and control groups, with a lesser increase in the n-3 PUFA group, without statistical significance. Metaregression showed no correlation between the amounts or duration of n-3 PUFA intake and their lipid-modulating effects.


In our meta-analysis, n-3 PUFA consumption significantly lowered the serum triglyceride levels. No significant changes were found on the degrees of low-density lipoprotein cholesterol reduction and total cholesterol or high-density lipoprotein cholesterol elevation effects.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center